A recent study by the Cleveland Clinic has revealed that popular obesity injections like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) may offer less weight loss in real-world scenarios compared to clinical trials. The research, published in the Obesity Journal, analyzed nearly 8,000 patients with severe obesity and found that early discontinuation, lower-than-recommended doses, and lack of structured follow-up were key reasons behind the reduced effectiveness. Unlike trial participants who saw 15–20% weight loss, patients in everyday settings lost an average of only 2.2% of their body weight over 72 weeks. Moreover, only one in three achieved a clinically meaningful 5% reduction.
Experts stress that while these medications hold promise, real success depends on consistent medical supervision, proper dosing, and lifestyle support. Without ongoing care and behavioral guidance, the benefits seen in controlled environments are difficult to replicate in real life. The study underscores the need for a holistic obesity management plan that goes beyond medication to include diet, exercise, and long-term monitoring. Simply prescribing injections without support may leave patients underwhelmed and less likely to stick with treatment.